Skip to main content
. 2019 Nov 25;19:1140. doi: 10.1186/s12885-019-6321-x

Fig. 1.

Fig. 1

Expression levels of Cyr61 in ascites and serum of ovarian benign and malignant tumor Cyr61 levels in ascites and serum of ovarian serous adenocarcinoma patients (n = 66) were significantly higher than those of ovarian serous cystadenoma patients (n = 18). And the ascites Cyr61 level was much higher than that of serum